Yijie Wu
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy.
Journal: Journal of hematology & oncology
Published: March 04, 2026
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: October 20, 2025
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer.
Journal: Science translational medicine
Published: August 13, 2025
ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.
Journal: Biochemical pharmacology
Published: May 31, 2025
Withdrawal notice to "ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis" [Biochemical Pharmacology 237 (2025) 116949].
Journal: Biochemical pharmacology
Published: May 27, 2025
Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy.
Journal: Science translational medicine
Published: May 07, 2025
Withdrawal notice to: ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.
Withdrawal notice to: ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis.
Journal: Biochemical pharmacology
Published: January 27, 2025
Showing 1-8 of 8
Last Updated: 09/26/2026